Marching in March to find a cure for Melanoma

Roz Petty and her team of Roz’s Warriors are back at it again, preparing to take up the challenge of the 2018 Bathurst Melanoma March.

Phase I: Clinical Trial Shows Some Promise for Investigational Drug for Melanoma

An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center and other institutions have reported.

Obesity Linked to Improved Outcomes in Men With Metastatic Melanoma

Obese men treated with targeted or immune therapies for metastatic melanoma had a 47% reduced risk of death compared with men who had a normal BMI, according to results from a retrospective multicohort analysis published in The Lancet Oncology.

Merck’s melanoma drug shows early promise for resistant cancers in PhI trial

Early news on a Merck drug candidate has researchers hopeful that the investigational therapy could be used to fight drug resistant cancers.

Cancer in the News

Feature Articles

Dermoscopic Criteria Identified for Diagnosing Melanoma in Situ

Aimilios Lallas, Ph.D., from Aristotle University in Thessaloniki, Greece, and colleagues conducted a diagnostic accuracy study with retrospective patient enrollment in three centers, including 1,285 individuals with histopathologically diagnosed MIS or other flat, pigmented skin tumors.

Read the full story

Posted in Melanoma In The News, Information

Beta blockers may improve response to immunotherapy in metastatic melanoma

Patients with metastatic melanoma who underwent treatment with immunotherapy derived a benefit when they also received beta blockers, according to study results.

Read the full story

Posted in Melanoma In The News, Information

Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma

Vemurafenib adjuvant therapy does not improve disease-free survival (DFS) among patients with resected stage IIC to IIIB melanoma, according to findings published in The Lancet Oncology.

Read the full story

Posted in Melanoma In The News, Clinical Trials

ctDNA Can Flag Pseudoprogression in Melanoma Treated With Immunotherapy

Circulating tumor DNA (ctDNA) can help differentiate what is known as pseudoprogression from true progression of disease in patients with melanoma who are treated with programmed death 1 (PD-1) inhibitors, according to a new study.

Read the full story

Posted in Melanoma In The News, Information

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories